ArticlePloS one2016
The Largest Known Survival Analysis of Patients with Brain Metastasis from Thyroid Cancer Based on Prognostic Groups.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The 2024 revised clinical guidelines on the management of thyroid tumors by the Japan Association of Endocrine Surgery.Endocrine journal · 2025Guideline
- Clinical and molecular features associated with the presence of brain metastases and survival in patients with advanced thyroid cancer.The oncologist · 2026Article
- Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi-Center Retrospective Cohort.Head & neck · 2026Article
- A differentiated thyroid carcinoma-specific graded prognostic assessment for brain metastases: derivation in a 10,306-patient cohort and external validation.Journal of neuro-oncology · 2026Article
- Usefulness of local therapy for distant metastases of differentiated thyroid cancer.European thyroid journal · 2025Review
- Diagnosis and management of brain metastasis from thyroid cancer.Endocrine oncology (Bristol, England) · 2025Review
- Incidence and gender difference of brain metastases in newly diagnosed follicular thyroid cancer patients.European thyroid journal · 2024Article
- Primary Central Nervous System Lymphoma (PCNSL) Following Thyroid Cancer Surgery: A Case Report of Misdiagnosed Brain Metastasis and Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Article
- Surgical management of metastatic Hürthle cell carcinoma to the skull base, cortex, and spine: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Clinical characteristics, treatment, and long-term outcome of patients with brain metastases from thyroid cancer.Clinical & experimental metastasis · 2023Article
- Multi-Omics and Management of Follicular Carcinoma of the Thyroid.Biomedicines · 2023Review
- Long-term survival of patients with intracranial metastases from thyroid cancer presenting with seizures: a case report and literature review.Translational cancer research · 2023Article
- Screening and treatment of brain metastasis from papillary thyroid carcinoma: a case series.Thyroid research · 2023Article
- Rare sites of metastases in patients with differentiated thyroid carcinoma and added value of SPECT/CT over planar whole body radioactive iodine scan.European journal of hybrid imaging · 2022Article
- Article
- Prognostic factors to predict the efficacy of surgical interventions against brain metastasis secondary to thyroid cancer.European thyroid journal · 2022Article
- Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system.Cancer medicine · 2022Review
- Metastatic brain lesion as the initial presentation of follicular thyroid carcinoma.Surgical neurology international · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo analyze the clinical features and prognostic factors associated with the survival of patients with a very rare occurrence of brain metastasis (BM) from differentiated thyroid cancer (DTC). METHODS AND MATERIALS: A total of 37 patients with DTC who were diagnosed with BM between 1995 and 2014 were included. We reviewed the clinical characteristics, treatment modalities, and image findings of BM. Factors associated with survival were evaluated, and the patients were divided into three prognostic groups (Groups A, B, and C) for comparative analysis.
resultsThe median age at BM was 63 years, and the median time from initial thyroid cancer diagnosis to BM was 3.8 years. The median survival and the 1-year actuarial survival rate after BM were 8.8 months and 47%, respectively. According to univariate and multivariate analyses, four good prognostic factors (GPFs) were identified including age ≤ 60 years, PS ≤ ECOG 2, ≤ 3 BM sites, and without extracranial metastasis prior to BM. Three prognostic groups were designed based on age and number of remaining GPFs: patients ≤ 60 years of age with at least 2 GPFs (Group A) had the most favorable prognosis with a median survival of 32.8 months; patients ≤ 60 years of age with fewer than 2 GPFs and those > 60 years of age with at least 2 GPFs (Group B) had an intermediate prognosis with a median survival of 9.4 months; and patients > 60 years of age with fewer than 2 GPFs (Group C) had the least favorable prognosis with a median survival of 1.5 months.
conclusionsThe survival of patients with BM form DTC differed among the prognostic groups based on the total number of good prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.